Thalamic Atrophy Is Associated with Development of Clinically Definite MS

被引：0
|
作者：
Zivadinov, Robert [1 ]
Havrdova, Eva [2 ]
Bergsland, Niels [1 ]
Tyblova, Michaela [3 ]
Hagemeier, Jesper [1 ]
Seidl, Zdenek [2 ]
Dwyer, Michael [1 ]
Vaneckova, Manuela [2 ]
Krasensky, Jan [3 ]
Carl, Ellen [1 ]
Kalincik, Tomas [2 ]
Horakova, Dana [2 ]
机构：
[1] Buffalo Neuroimaging Anal Ctr, Buffalo, NY USA
[2] Charles Univ Prague, Prague, Czech Republic
[3] Buffalo Neuroimaging Anal Ctr, Prague, Czech Republic
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S51004
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis
    Zivadinov, Robert
    Havrdova, Eva
    Bergsland, Niels
    Tyblova, Michaela
    Hagemeier, Jesper
    Seidl, Zdenek
    Dwyer, Michael G.
    Vaneckova, Manuela
    Krasensky, Jan
    Carl, Ellen
    Kalincik, Tomas
    Horakova, Dana
    RADIOLOGY, 2013, 268 (03) : 831 - 841
  • [2] Slowing of cortical grey matter atrophy with teriflunomide is associated with delayed conversion to clinically definite MS
    Zivadinov, R.
    Dwyer, M. G.
    Carl, E.
    Thangavelu, K.
    Cavalier, S.
    Bergsland, N.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 321 - 322
  • [3] Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
    Zivadinov, Robert
    Dwyer, Michael G.
    Carl, Ellen
    Poole, Elizabeth M.
    Cavalier, Steve
    Briassouli, Paraskevi
    Bergsland, Niels
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [4] Conversion to clinically definite multiple sclerosis is associated with lobule-specific atrophy of the cerebellum
    Bergsland, N.
    Uher, T.
    Horakova, D.
    Ramasamy, D.
    Vaneckova, M.
    Seidl, Z.
    Krasensky, J.
    Havrdova, E.
    Zivadinov, R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 548 - 549
  • [5] Slowing of whole brain volume loss with teriflunomide is associated with delayed conversion to clinically definite MS
    Zivadinov, R.
    Dwyer, M.
    Carl, E.
    Poole, E.
    Cavalier, S.
    Bergsland, N.
    Roesch, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 872 - 872
  • [6] Diagnostic MRI criteria: Prediction of conversion to clinically definite MS
    Barkhof, F
    Filippi, M
    Comi, G
    NEUROLOGY, 2002, 58 (07) : A157 - A157
  • [7] SEE-SAW NYSTAGMUS IN A PATIENT WITH CLINICALLY DEFINITE MS
    SAMKOFF, LM
    SMITH, CR
    EUROPEAN NEUROLOGY, 1994, 34 (04) : 228 - 229
  • [8] Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis
    Steckova, Tereza
    Hlustik, Petr
    Sladkova, Vladimira
    Odstrcil, Frantisek
    Mares, Jan
    Kanovsky, Petr
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 342 (1-2) : 62 - 68
  • [9] Connecting white matter injury and thalamic atrophy in clinically isolated syndromes
    Henry, Roland G.
    Shieh, Mason
    Amirbekian, Bagrat
    Chung, SungWon
    Okuda, Darin T.
    Pelletier, Daniel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 282 (1-2) : 61 - 66
  • [10] A profile of patients at high risk for the development of clinically definite MS (CDMS): The first report of the CHAMPS study
    Jacobs, LD
    Beck, RW
    Brownscheidle, CM
    Kinkel, RP
    Miller, AE
    Murray, TJ
    Simon, JH
    Blanchard, NL
    Lloyd, KJ
    Sandrock, AW
    Simonian, NA
    NEUROLOGY, 1999, 52 (06) : A495 - A495
12345